315 related articles for article (PubMed ID: 15265637)
1. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
2. Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist.
Perera PY; Lichy JH; Mastropaolo J; Rosse RB; Deutsch SI
Eur Neuropsychopharmacol; 2008 Nov; 18(11):814-9. PubMed ID: 18674888
[TBL] [Abstract][Full Text] [Related]
3. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
Levin ED; Petro A; Caldwell DP
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):581-6. PubMed ID: 15866361
[TBL] [Abstract][Full Text] [Related]
4. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain.
Long KD; Mastropaolo J; Rosse RB; Manaye KF; Deutsch SI
Brain Res Bull; 2006 May; 69(6):626-30. PubMed ID: 16716829
[TBL] [Abstract][Full Text] [Related]
5. Chronic nicotine and dizocilpine effects on regionally specific nicotinic and NMDA glutamate receptor binding.
Levin ED; Tizabi Y; Rezvani AH; Caldwell DP; Petro A; Getachew B
Brain Res; 2005 Apr; 1041(2):132-42. PubMed ID: 15829222
[TBL] [Abstract][Full Text] [Related]
6. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
7. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
[TBL] [Abstract][Full Text] [Related]
8. Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent.
Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J
Life Sci; 2003 Sep; 73(18):2355-61. PubMed ID: 12941437
[TBL] [Abstract][Full Text] [Related]
9. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
[TBL] [Abstract][Full Text] [Related]
10. Topiramate antagonizes MK-801 in an animal model of schizophrenia.
Deutsch SI; Rosse RB; Billingslea EN; Bellack AS; Mastropaolo J
Eur J Pharmacol; 2002 Aug; 449(1-2):121-5. PubMed ID: 12163115
[TBL] [Abstract][Full Text] [Related]
11. A competitive antagonist of NMDA receptors CGP 40116 attenuates experimental symptoms of schizophrenia evoked by MK-801.
Zajaczkowski W; Czyrak A; Wedzony K
Pol J Pharmacol; 2003; 55(5):703-11. PubMed ID: 14704466
[TBL] [Abstract][Full Text] [Related]
12. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
13. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities.
Rujescu D; Bender A; Keck M; Hartmann AM; Ohl F; Raeder H; Giegling I; Genius J; McCarley RW; Möller HJ; Grunze H
Biol Psychiatry; 2006 Apr; 59(8):721-9. PubMed ID: 16427029
[TBL] [Abstract][Full Text] [Related]
14. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat.
Klamer D; Zhang J; Engel JA; Svensson L
Behav Brain Res; 2005 Apr; 159(1):95-103. PubMed ID: 15795002
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.
Seillier A; Giuffrida A
Behav Brain Res; 2009 Dec; 204(2):410-5. PubMed ID: 19716985
[TBL] [Abstract][Full Text] [Related]
16. Exogenously administered D-serine failed to potentiate the ability of MK-801 to antagonize electrically precipitated seizures in nonhandled control and stressed mice.
Long KD; Mastropaolo J; Rosse RB; Deutsch SI
Eur Neuropsychopharmacol; 2007 Jan; 17(1):53-7. PubMed ID: 16616833
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic implications of a selective alpha7 nicotinic receptor abnormality in schizophrenia.
Deutsch SI; Rosse RB; Schwartz BL; Weizman A; Chilton M; Arnold DS; Mastropaolo J
Isr J Psychiatry Relat Sci; 2005; 42(1):33-44. PubMed ID: 16134405
[TBL] [Abstract][Full Text] [Related]
18. Behavioral consequences of methyllycaconitine in mice: a model of alpha7 nicotinic acetylcholine receptor deficiency.
Chilton M; Mastropaolo J; Rosse RB; Bellack AS; Deutsch SI
Life Sci; 2004 May; 74(25):3133-9. PubMed ID: 15081578
[TBL] [Abstract][Full Text] [Related]
19. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
[TBL] [Abstract][Full Text] [Related]
20. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons.
Aracava Y; Pereira EF; Maelicke A; Albuquerque EX
J Pharmacol Exp Ther; 2005 Mar; 312(3):1195-205. PubMed ID: 15522999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
